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 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction GSK-3 is the neuronal microtubule-associated protein tau. Tau isBirds are attractive subjects for research in ecological, neurobio-
logical and behavioral evolution [1,2]. Of particular interest is the
neurobiology of birds, which is conspicuously different from that
of other vertebrates. Birds display a unique neuroanatomy archi-
tecture and are known for their robust neurogenesis and neuronal
replacement in comparison with other organisms [3,4]. Birds are
also notable for their complex natural behaviors such as vocal com-
munication, learning and social living [1,5]. Recent decoding of the
chicken (Gallus gallus), domestic turkey (Meleagris gallopavo) and
zebra ﬁnch (Taeniopygia guttata) genomes [6–8] should provide
information that will reveal biochemical and genomic elements
underpinning the unique properties of birds.
Glycogen synthase kinase-3 (GSK-3) is a highly conserved ser-
ine/threonine kinase that is a critical regulator of neuronal signal-
ing, cognition and behavior. Abnormal GSK-3 activity promotes cell
apoptosis, inhibits neuronal growth and leads to changes in brain
morphology and cognitive abilities such as learning and memory
and mental and social behavior [9–15]. One important target ofchemical Societies. Published by E
kelman).a principle regulator of microtubule stability and an integral player
in neuron morphology, outgrowth and plasticity [16–18]. Hyper-
phosphorylation of tau alters neuronal maturation and plasticity
and is a hallmark of the tangle pathology detected in Alzheimer’s
disease [16,17,19]. GSK-3 phosphorylates tau at several sites [20–
22] implicated in Alzheimer’s pathogenesis [22–25]. Serine 396 is
a unique and a predominant phosphorylation site of GSK-3 [22],
and, like many other GSK-3 substrates, its phosphorylation re-
quires prior phosphorylation, in this case at serine 404 [26].
Mammalian GSK-3 exists as two isoforms, a and b, encoded by
two different genes [27]. Their distinct biological roles are not fully
known. Here we sought to study the functional and evolutionary
signiﬁcance of each GSK-3 isoform. We report that unlike other
vertebrates, the GSK-3a gene is missing in birds. Additionally, un-
like other substrates tested, lack of GSK-3a resulted in a robust
reduction in tau phosphorylation in the adult bird brain.
2. Materials and methods
2.1. Materials
Monoclonal antibody that recognizes GSK-3a and b was pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA),lsevier B.V. All rights reserved.
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(Billerica, MA, USA). Anti-b-catenin, anti-phospho-CREB (Ser 129/
133) and anti-tau were purchased from Cell Signaling Technologies
(Beverly, MA, USA). Anti phospho-tau antibodies (Ser 202, Ser 396,
Ser 404) were from Cell Signaling Technologies and Millipore.
2.2. Bioinformatic analysis
Sequence searches of NCBI databases were performed using the
BLAST programs. Protein, genomic and transcribed (EST) sequence
databases were queried with known GSK-3 sequences. Potential
GSK-3 protein sequences were further speciﬁcally examined to
verify their identity. Sequences of GSK-3 proteins were aligned
using BLASTp, meme [28] and GLAM-2 [29] programs and the
corresponding coding regions were edited with the Se-Al sequence
alignment editor (Andrew Rambaut, http://tree.bio.ed.ac.uk/
software/seal/). A phylogenetic tree was calculated with the
PHYML program, version 2.4.4, with four substitution rate catego-
ries, the HKY nucleotide substitution model and other default
parameters to estimate the Ts/Tv ratios, gamma shape parameters
and invariant proportions. These parameters were then used with
100 bootstrap replicates. Corresponding trees were found with
different combinations of GSK-3 sequences and with the RaxML
program [30] (data not shown).
2.3. Animals
Zebra ﬁnches were obtained from a breeding colony in Tel Aviv
University, and house sparrows were collected under the Israel
Nature and National Parks Protection Authority permit. Chicken
embryos were used at day 18 (three days prior to hatching).
GSK-3a KO mice and their wild-type littermates were generated
and maintained as previously described [10,31]. Animals were
housed in the Toronto Center for Phenogenomics (TCP) in Toronto,
Canada. Hippocampal samples for western blot analysis were
isolated from 4 month old GSK-3a KO (n = 4) and wild-type
(WT) mice (n = 4). Animal use was approved by the Tel Aviv
University Institutional Animal Care and Use Committee or TCP
as appropriate.
2.4. Tissues
Brains, livers and hearts were removed from birds (adult or em-
bryos as indicated) or mice and frozen in liquid nitrogen. Frozen
tissues were homogenized with buffer H (10 to 250 mM b-
glycerophosphate, 10% glycerol, 1 to 7.5 mM EGTA, 1 to 5 mM
EDTA, 50 mM NaF, 5 mM sodium pyrophosphate, 0.5 mM ortho-
vanadate, 1 mM benzamidine, 5 lg/ml leupeptin, 25 lg/ml aproti-
nin, 5 lg/ml pepstatin, and 0.5% Triton X100). Equal amount of
proteins (60 lg) were subjected to gel electrophoresis followed
by immunoblot analysis using indicated antibodies.
2.5. Statistics
Data were analyzed with Origin Professional 6.0 software using
the Student’s t-test. Data were considered signiﬁcant at p < 0.05.
3. Results
3.1. GSK-3a gene is missing from bird genomes
By comparing GSK-3 sequences from diverse organisms (Fig. 1A
and S1), we found that the a and b isoforms split from a common
precursor approximately at the time of emergence of vertebrates.
Surprisingly, although both GSK-3a and b genes are present andhighly conserved in ﬁsh, amphibians, reptiles and mammals, the
GSK-3a gene was missing from the genomes of chicken, domestic
turkey and zebra ﬁnch, the three bird species with available draft
genomes and extensive transcriptomic data [6–8]. The absence of
GSK-3a from these genomes and transcriptomes of three diverse
bird species suggests this is a common loss in the avian species.
The presence of GSK-3a in various ﬁsh, amphibians and lizards
clearly indicates that the GSK-3a gene was lost after the split of
ancestral birds from reptilians. Sequence identities between GSK-
3b from human and chicken and between human and zebra ﬁnch
are 96% and 94%, respectively.
To verify our ﬁndings experimentally, protein expression pat-
terns of GSK-3a and b were examined by western blot analysis
in mouse and three different bird species: domestic chicken, house
sparrow (Passer domesticus) and zebra ﬁnch. Two different antibod-
ies were used; both recognize highly conserved regions within
GSK-3a and b. One monoclonal antibody recognizes both GSK-3s
and the other recognizes a phospho-tyrosine (Tyr 279 and Tyr
216 of GSK-3a and b, respectively). The two bands corresponding
to GSK-3a and b were clearly observed in mouse brains (Fig. 1B),
but GSK-3a was not detected in samples from the brains of any
of the birds (Fig. 1B) or in other bird tissues such as heart and liver
(Fig. 1C).3.2. Lack of GSK-3a results in reduced tau phosphorylation in the adult
bird brain
We next examined if lack of GSK-3a in birds affects tau phos-
phorylation. Brain homogenates of birds (house sparrow and ze-
bra ﬁnch) were subjected to western blot analysis using various
anti-phospho-tau antibodies. A signiﬁcant reduction in tau phos-
phorylation at the known GSK-3 phosphorylation site, Ser 396
[22], was detected in the samples from bird’s brain as compared
with those from mouse brain (Fig. 2A, tau isoforms migrate as
52–72 kDa bands). This was not due to loss of tau, as ‘total’
tau was readily detected in bird brains (Fig. 2A). The data dem-
onstrating that the anti-phospho-tau antibody recognizes bird
tau is discussed in the following section. As shown in Fig. 2A,
the bird tau was phosphorylated at the ‘priming site’ Ser 404
[26], and at Ser 202, a site phosphorylated by multiple kinases
including GSK-3 [20] (Fig. 2A). Quantiﬁcation of the phosphory-
lated bands revealed no signiﬁcant differences in the ratios of
phosphorylated tau (Ser 404, Ser 202) to total tau in birds or
mice (Fig. 2A). These data demonstrated that tau can be phos-
phorylated at additional sites and validated the signiﬁcance in
the observed reduction of tau phosphorylation at Ser 396 in bird
brain.
b-Catenin is a key effector in the Wnt signaling pathway and a
known substrate of GSK-3 [32]. Phosphorylation of b-catenin by
GSK-3 enhances its proteosomal degradation [32]. Hence, lack of
GSK-3a could lead to elevation in b-catenin levels. However, b-
catenin levels in bird brains were comparable to those observed
in the mouse brain (Fig. 2B). Similarly, no signiﬁcant changes were
observed in the phosphorylation of another GSK-3 target-CREB
(cAMP response element binding protein) [33]. Quantiﬁcation of
phosphorylated CREB revealed no signiﬁcant differences in the ra-
tios of phospho-CREB to total CREB in birds vs. mice.
Finally, experiments were conducted in brains of GSK-3a
knockout (KO) mice [31]. As shown in Fig. 2C, phosphorylation of
tau at Ser 396 was signiﬁcantly lower in brains from GSK-3a KO
mice as compared those of WT mice. No signiﬁcant differences
were observed in b-catenin levels or the ratios of phospho-CREB
to total CREB in GSK-3a KO vs. WT brain samples (Fig. 2C). It ap-
pears that GSK-3 isoforms are functionally redundant in regulation
of b-catenin (as also shown in [34]) and CREB phosphorylation. In
Fig. 1. GSK-3a is missing in birds. (A) Schematic representation of a phylogenetic tree calculated from multiple sequence alignment of diverse GSK-3 sequences (see Fig. S1
for complete data). Triangles cluster several species of the noted groups. Alpha and Beta labeled arrows show groups where GSK-3a and GSK-3b sequences, respectively, were
found. Note that a GSK-3 gene from a lamprey (Petromyzon marinus), a basal jawless vertebrate, was found within the GSK-3b group and that GSK-3 sequences from non-
vertebrate basal chordates (Amphioxus, a cephalochordate, and Saccoglosus, a hemichordate) were placed in groups outside the a and b GSK-3 sequences (Fig. S1). The
unicellular choanoﬂagellates (the ancestors of sponges) were used as the out group to root the tree. No GSK-3a genes were found in birds. Bootstrap values are shown. (B)
Expression of GSK-3 proteins in brains of chicken embryo (day 18), house sparrow, zebra ﬁnch and mouse. Brain tissue extracts (60 lg) were subjected to western blot
analysis using anti-GSK-3 (upper panel) or anti-phospho-GSK-3 (Tyr 216/279) (lower panel) antibodies. Shown are representative gels from three independent experiments.
Fig. 2. Lack of GSK-3a results in reduced tau phosphorylation. (A) Brain tissue extracts (60 lg) prepared from house sparrow, zebra ﬁnch and mouse were subjected to gel
electrophoresis and western blot analysis using the indicated anti-phospho-tau (Ser 396, Ser 404 and Ser 202) antibodies. Densitometry analysis of the phosphorylated
fraction of tau (phospho-tau/total tau) is shown in the right panel and is fold of the phosphorylated fraction obtained for mouse tau that was designated to 100%. Results are
mean ± S.E.M. (n = 3). Tau isoforms migrate as proteins ranging from 52 to 72 kDa. (B) The same as A except that anti-b-catenin, anti-phospho-CREB (Ser129/133), and anti-
CREB antibodies were used. Expression of actin is shown to conﬁrm equal loading. (C) Hippocampus tissue extracts (60 lg) prepared from GSK-3a KO andWT were subjected
to western blot analysis using the same antibodies described in (A). Densitometry analysis of phosphorylated tau is shown in the right panel as a mean ± S.E.M. (n = 4). Gels
are representative of three individuals of each species of bird and four KO and four WT mice.
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Fig. 3. Phosphorylation of tau in bird embryos. (A) Phosphorylation of tau in
embryonic brain. Tissue extracts prepared from brains of zebra ﬁnch embryos (day
9–10 days) or adults were subjected towestern blot analysis using anti-phospho-tau
and anti-tau antibodies. Densitometry analysis of phospho-tau (Ser 396) is shown in
the right panel as mean ± S.E.M. (n = 3). (B) The same experiment as described A
except that anti-GSK-3 antibody was used and a mouse brain sample was added as a
reference. Expression of GSK-3a and GSK-3b is shown.
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by GSK-3b, suggesting that GSK-3 isoforms have distinct properties
with respect to tau phosphorylation.
3.3. Role for GSK-3b in phosphorylating embryonic tau
Our results raised the possibility that GSK-3b is unable to phos-
phorylate tau (Fig. 2A). On the other hand, phosphorylation of tau
could be dependent on cellular context. It is known that expression
and phosphorylation of tau is developmentally regulated [35–37]
and this prompted us to evaluate tau phosphorylation in the bird
embryos. Brain homogenates prepared from zebra ﬁnch embryos
(day 9–10) were subjected to gel electrophoresis and blots were
probed for phosphorylated tau. Different tau isoforms were de-
tected in embryos than in adult brain (Fig. 3A). Phosphorylation
at Ser 396 was very weak in adult brains, whereas it was readily
detected in the embryonic samples (Fig. 3A). Notably, these results
conﬁrmed the ability of the anti-phospho-tau antibody to recog-
nize bird tau. In addition, we show that embryonic tau phosphor-
ylated at Ser 396 was comparable with that of mouse further
validating the ability of this antibody to recognize bird’s tau
(Fig. S2)). Since GSK-3b is the isoform expressed in the embryo
(Fig. 3B), it is suggested that GSK-3b is responsible for the phos-
phorylation of the embryonic tau isoforms, although, we cannot
ignore the possibility the other protein kinases such as mitogen
activated protein kinase (MAPK) and CDK-5 may contribute to
tau phosphorylation at this site as well [20].
4. Discussion
Gene duplication is considered a fundamental mechanism for
functional innovation during evolution [38]. The emergence of
two GSK-3 isozymes and their retention during vertebrate evolu-
tion suggests an important diversity in their biological functions.
Although we do not know how the GSK-3a gene was deleted from
the bird lineage or why, the lack of GSK-3a likely inﬂuenced the
biology of the avian species. It is possible that high doses of GSK-
3 activity (resulting from expression of two genes) had deleterious
effects in birds, and that this was remedied by deletion of the GSK-
3a gene from the ancestral bird genome. Studies in mammalian
models indicate that lack of GSK-3a or inhibition of GSK-3 activity
alters neuronal architecture and cognitive activities [10–12,14].For example, abnormalities in brain structure were observed in
GSK-3a knockout mice [10], and inhibition of GSK-3 or deletion
of one allele of GSK-3bmimicked the activity of the mood stabilizer
lithium and improved depressive-like behavior [14,39]. Interest-
ingly, hyperactivity of GSK-3 in mouse brain results in socialization
deﬁcits [12]. It is thus tempting to speculate that lack of GSK-3a
contributed to the unique brain organization and anatomy of birds
and was responsible, at least in part, for their complex cognitive
abilities including navigation, learning and memory and social
behavior [1,2]. The dramatic reduction in tau phosphorylation at
the known GSK-3 phosphorylation site observed in bird brains (a
phenomenon that was reproduced in brains of GSK-3a KO mice),
as well as the demonstrated role of reduced tau phosphorylation
in neuronal activity and synaptic plasticity [17,40,41], suggests a
possible link between lack of GSK-3a, tau, and avian brain
function.
Little is known about tau protein in birds. One study character-
ized tau from chicken and conﬁrmed its ability to promote micro-
tubule assembly [37]. It also showed that tau expression was
developmentally regulated, and that its phosphorylation was more
extensive in the embryo than after hatching [37]. We report here a
similar observation in which tau phosphorylation at Ser 396 was
signiﬁcantly higher in zebra ﬁnch embryos than in adult brains.
This site is predominantly phosphorylated by GSK-3 [22,26]
(although we should note that other protein kinases such as MAPK
and CDK-5 were shown to phosphorylate this site [20]), indicating
that GSK-3b can phosphorylate embryonic tau. This raises the sup-
position that GSK-3a and GSK-3b have distinct roles in phosphor-
ylating tau in adult and embryonic brain in non-bird vertebrates.
Future studies should investigate this question. Finally, inhibition
of GSK-3 and reduced tau phosphorylation is thought to beneﬁt pa-
tients with Alzheimer’s disease [42–44]. Our data support the
hypothesis that speciﬁc inhibition of GSK-3a may be useful for
therapeutic intervention in these diseases. In summary, birds
might be regarded as natural GSK-3a knockout organisms and will
serve as a novel model to further our understanding of the distinct
functions of GSK-3 isoforms.
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